The effect of subcutaneous recombinant Human Erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy

Journal of the Pakistan Medical Association

Volumn 48, Issue 5, 1998, Pages 127-131

  Malik, Imtiaz A ^a   Khan, Zubair K ^a   Hakimali, Azra ^a   Sabih, Mehreen ^a   Rehman, Gul ^b  

^a National Cancer Institute   (Pakistan)

^b Nishterabad Hospital   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT PROTEIN;

ANEMIA; ARTICLE; BLOOD; BLOOD TRANSFUSION; DAILY LIFE ACTIVITY; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; NEOPLASM; OVARY TUMOR; QUALITY OF LIFE; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION;

ACTIVITIES OF DAILY LIVING; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CISPLATIN; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; QUALITY OF LIFE; RECOMBINANT PROTEINS; RETICULOCYTE COUNT;

EID: 0032065310     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Gale, R.P. Antineoplastic chemotherapy myelosuppression: Mechanism and new approaches. Exp. Hematol., 1985;13(Suppl 16):3-7.
2. Okamoto, H., Saijo, N., Shinkai, T. et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann. Oncol., 1992;3:819-824.
3. Skillings, J.R., Sridhar, F.G., Wong, C. et al. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study. Am. J. Clin. Oncol., 1993;16:22-25.
4. Walker, R.H. Tranfusion risks. Am. J. Clin. Pathol., 1987;88:374-378.
5. Handbook of transfusion medicine. HMSO Publications. London, 1989.
6. Dodd, R. Y. The risk of transfusion-transmitted infection. N. Engl. J. Med., 1992;327:419-421.
7. Tartter, P.I., Burrows, L. and Kirschner, P. Perioperative blood transfusion adversely affects prognosis after resection of stage I (Subset NO) Non-oat cell lung cancer. J. Thoracic Cardiovas. Surg., 1984;88:659-662.
8. Hyman, N.H., Foster, R.S., DeMeules, J.E. et al. Blood transfusion and survival after lung cancer resection. Am. J. Surg., 1985;149:502-507.
9. Tartter, P.I., Burrows, L., Papatestas, A.E. et al. Perioperative blood transfusion has prognostic significance for breast cancer. Surgery, 1985;97:225-229.
10. Rosenberg, S.A., Seipp, C.A., White, D.E. et al. Perioperative blood transfusion are associated with increased rates of recurrence and decreases survival in patients with high-grade soft tissue sarcomas of the extremities. J. Clin. Oncol., 1985;3:698-709.
11. Beyon, J., Davies, P.W., Billings, P.J. et al. Perioperative blood transfusion increases the risk of recurrence in colorectal cancer. Dis. Colon Rectum, 1989;29:975-979.
12. Johnson, S. and Anderson, M. Adverse effects of perioperative blood transfusions in patients with colorectal cancer. Eur. J. Surg. 1992;158:419-425.
13. Blumberg, N. and Heal, J.M. Effect of transfusion on immune function. Cancer recurrence and infection. Arch. Pathol. Lab. Med., 1994;118:371-379.
14. Rothmann, S.A., Paul, P., Weick, J.M. et al. Effect of cisdiamminedichloroplatinum on erythropoietin production and 2hematopoietic progenitor cells. Int. J. Cell. Cloning., 1985;3:415-423.
15. Piroso, E., Erslev., A. and Caro, J. Inappropriate increase in erythropoietin titers during chemotherapy. Am. J. Hematol., 1989;32:248-254.
16. Miller, C.B., Jones, R.J., Piantadosi, S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med., 1990;322:1689-1692.
17. Schapira, L., Antin, J.H., Ransil, B.J. et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood, 1990;76:2354-2359.
18. Bray, G.L. and Reaman, G.H. Erythropoietin deficiency: A complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am.J. Pediatr. Hematol. Oncol., 1991;13:426-430.
19. Hasegawa, I. and Tanaka, K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol. Oncol., 1992;46:65-68.
20. Erslev, A.J. Erythropoietin. N. Engl. J. Med., 1991;324:1339-1344.
21. Winearls, C.G., Oliver, D.O., Pippard, M.J. et al. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet, 1986;ii:1175-1178.
22. Eschbach, J.W., Egrie, J.C., Downing, M.R. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N. Engl. J. Med., 1987;316:73-78.
23. Fischl, M., Galpin, J.E., Levine, J.D. et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl. J. Med., 1990;322:1488-1493.
24. Gebbia, V., Palmeri, S., Valenza, R. et al. The in vivo effects of recombinant human erythropoietin on cisdiamminodichloroplatinum-induced anemia in golden Syrian hamsters. In vivo, 1991;5:149-152.
25. Oster, W., Herrman, F., Gamm, H. et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration, J. Clin. Oncol., 1990;8:956-962.
26. Ludwing, H., Fritz, E., Kotzmann, H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med., 1990;322:1693-1696.
27. Ponchio, L. Beguin, Y., Farina, G. et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anemia. Haematologica, 1992;277:494-501.
28. Matsumoto, T., Endru, K., Kamisango, K. et al. Effect of recombinant human erythropoietin on anticancer drug-induced anemia. Br. J. Haematol., 1990;75:463-468.
29. James, R.D., Wilkinson, P.M., Belli, F. et al. Recombinant human erythropoietin in patients with ovarian cancer and anemia secondary to cisplatin and carboplatin chemotherapy: Preliminary results. Acta Haematologica, 1992;87 (Suppl I):12-15.
30. Geebbia, V., Russo, A., Gebbia, N. et al. Recombinant human erythropoietin accelerates recovery from cisplatin induced anemia in cancer patients: Preliminary results. Cancer J., 1991;4:343-347.
31. Miller, C.B., Plantanias, L.C., Mills, S.R. et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J. Natl. Cancer, Inst., 1992;84;98-103.
32. Case, D.C., Bukowski, R.M., Carey, R.W. et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J. Natl. Cancer Inst., 1993;85:801-806.
33. Marlman, M., Reichman, B., Hakes, T. et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecologic Oncol., 1993;49:172-176.
34. Gamucci, T., Thorel, M.F., Frasca, A.M. et al. Erythro-poietin for the prevention of anemia in neoplastic patients treated with cisplatin. Eur. J. Cancer, 1993;29A(Suppl 2):S13-S14.
35. Cascinu, S., Fedeli, A., Del-Ferro, E. et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J.Clin. Oncol., 1994;12:1058-1062.
36. Henry, D.H. and Abels, R.L. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin. Oncol., 1994;21:21-28.
37. Leitgeb, C., Pecherstorfer, M., Fritz, E. et al. Quality of life in chronic anemia of cancer during treatment and recombinant human erythropoietin. Cancer, 1994;73:2535-2542.
38. McMahon, F.G., Vargas, R., Ryan, M. et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. Blood, 1990;76:1718-1722.
39. Horl, W.H. Optimal route of administration of erythropoietin in chronic renal failure patients. Intravenous versus subcutaneous. Acta Hematol., 1992;87 (Suppl 1):16-19.
40. Bergrem, H., Danielson, B.G., Eckardt, K.U. et al. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer, C., Koch, K.M., Scigalla, P. et al. eds. Erythropoietin: Molecularphysiology and clinical applications. New York, Marcel Dekker, 1993, pp. 265-273.
41. Campos, E.D., Radford, J., Steward, W. et al. Clinical and in- vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer J. Clin. Oncol., 1995;13:1623-1631.